Explore our range of useful resources below, designed to support you with decision making in your local area. You can download the files to refer to later.

For MAYZENT®▼ (siponimod) prescribing information click here

For KESIMPTA®▼ (ofatumumab) prescribing information click here

For GILENYA®▼ (fingolimod) prescribing information click here

MAYZENT®▼ (siponimod) formulary application pack

Template document detailing information that may be useful to support you with your local formulary submission for MAYZENT treatment.

Registration is required to access this resource.

Download resource

Thumbnail image of Mayzent logo

MAYZENT®▼ (siponimod) NICE and SMC guidance

Visit summaries of the guidance and recommendations of NICE and SMC for the use of MAYZENT in SPMS patients with active disease.

These documents contain links which will take you to external websites over which Novartis Pharmaceuticals UK Limited has no ownership or control. Novartis Pharmaceuticals UK Limited accepts no responsibility for the content, accuracy, or your use of linked websites.

NICE  SMC  

 

MAYZENT clinical protocol

The purpose of this document is to provide you with a template and useful information to support with the development of your local clinical protocol for MAYZENT treatment.

Registration is required to access this resource.

Download resource

 
 

KESIMPTA supporting NHS recovery

See Joela Mathews, Lead Neuroscience Pharmacist at Barts Health NHS Trust, discuss how incorporating KESIMPTA into the MS patient pathway could help support the reset and recovery of local MS services.

Thumbnail image of KESIMPTA® (ofatumumab) formulary application pack

KESIMPTA clinical protocol

Key information for writing or reviewing a clinical protocol to support the local implementation of KESIMPTA for the treatment of relapsing forms of MS with active disease.

Registration is required to access this resource.

Download resource

 

Thumbnail image of KESIMPTA® (ofatumumab) formulary application pack

KESIMPTA formulary application pack

Template document detailing information that may be useful to support you with your local formulary submission for KESIMPTA treatment.

Registration is required to access this resource.

Download resource

 

 

Image of Kesimpta logo

If you are also a UK healthcare professional you can click below to view more information on KESIMPTA®▼ (ofatumumab).

This link will take you to promotional information about Novartis products, therapy area materials and professional resources.

Show more

Image of Gilenya logo

If you are also a UK healthcare professional you can click below to view more information on GILENYA® (fingolimod).

This link will take you to promotional information about Novartis products, therapy area materials and professional resources.

Show more

Image of Mayzent logo

If you are also a UK healthcare professional you can click below to view more information on MAYZENT®▼ (siponimod).

This link will take you to promotional information about Novartis products, therapy area materials and professional resources.

Show more

 

NICE, National Institute for Health and Care Excellence; SMC, Scottish Medicines Consortium; SPMS, secondary progressive multiple sclerosis.

Rate this content: 
5
Average: 5 (1 vote)
UK | August 2021 | 132036

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]